PYREXIA is the #6 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 3,631 FDA adverse event reports linking PEMBROLIZUMAB to PYREXIA. This represents approximately 2.4% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
PYREXIA3,631 of 152,954 reports
PYREXIA is a less commonly reported adverse event for PEMBROLIZUMAB, but still significant enough to appear in the safety profile.
Other Side Effects of PEMBROLIZUMAB
In addition to pyrexia, the following adverse reactions have been reported for PEMBROLIZUMAB:
PYREXIA has been reported as an adverse event in 3,631 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is PYREXIA with PEMBROLIZUMAB?
PYREXIA accounts for approximately 2.4% of all adverse event reports for PEMBROLIZUMAB, making it a notable side effect.
What should I do if I experience PYREXIA while taking PEMBROLIZUMAB?
If you experience pyrexia while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.